Miguel A. Perez-Hernandez

Santa Cruz De Tenerife, CN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Serum neurofilament light chain as a biomarker of inflammatory activity in relapsing-remitting multiple sclerosis: a real-world longitudinal cohort study.

Serum neurofilament light chain as a biomarker of inflammatory activity in relapsing-remitting multiple sclerosis: a real-world longitudinal cohort study.

Journal: Clinical chemistry and laboratory medicine

Published: June 12, 2026

Discriminating Relapsing-Remitting From Progressive Multiple Sclerosis Using Multidimensional Speech Biomarkers: An Independent Cohort Validation Study.

Discriminating Relapsing-Remitting From Progressive Multiple Sclerosis Using Multidimensional Speech Biomarkers: An Independent Cohort Validation Study.

Journal: Journal of voice : official journal of the Voice Foundation

Published: March 17, 2026

Voice analysis as a digital biomarker: A machine learning approach for automated multiple sclerosis classification.

Voice analysis as a digital biomarker: A machine learning approach for automated multiple sclerosis classification.

Journal: Multiple sclerosis and related disorders

Published: November 10, 2025

Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases.

Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases.

Journal: Neurologia

Published: September 17, 2024

Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.

Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.

Journal: Therapeutic advances in neurological disorders

Published: April 12, 2024

Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis.

Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: February 14, 2024

Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis.

Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis.

Journal: Patient preference and adherence

Published: January 12, 2024

Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale.

Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: January 03, 2024

Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 31, 2023

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.

Journal: Multiple sclerosis and related disorders

Published: September 19, 2023

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.

Journal: Neurologia

Published: March 09, 2023

Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.

Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.

Journal: Scientific reports

Published: November 30, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026